Good News, Bad News on Breast Cancer Drug
From Times Wire Reports
A breast cancer drug from Franco-German manufacturer Aventis can keep women alive longer than its leading rival but has more severe side effects, researchers said in Copenhagen.
Women who took docetaxel, marketed under the brand name Taxotere, survived for an average of 15.4 months, compared with 12.7 months for those taking Bristol-Myers Squibb Co.’s paclitaxel, marketed as Taxol. But they experienced more side effects such as fever, mouth ulcers and low white blood cells.
